Novel Pathways and Targeted Therapies for Gastric Cancer
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".
Deadline for manuscript submissions: closed (30 September 2020) | Viewed by 20635
Special Issue Editors
Interests: gastro-intestinal malignancies; molecular pathology; multimodality treatment; surgical oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
New epidemiological trends in gastric cancer (GC) in Western countries include an upward shift in the location of the primary (proximal) tumor and a relative increase of advanced and diffuse type (poorly cohesive) tumors. As a result, approaches to GC surgeries are becoming more individualized. Minimally invasive surgeries which spare organs are seen as both feasible and acceptable, even in patients with advanced GC, but must be followed-up with an adequate response after neoadjuvant treatment. The new goal of preoperative systemic therapy in patients with lymph node positive GC should be to achieve a complete nodal response. The molecular division of GC comes from three various parts of the world. Similarly, there are also three different standard treatment modalities for advanced GC combining local (surgery and radiotherapy) and systemic treatments. So far, the molecular classification of GC does not imply modality treatment. However, there is more and more evidence that some special molecular types of GC can be treated in different ways than that suggested by current clinical guidelines. Advanced GC with PD-L1 positive and MSI-H may exhibit the efficacy of anti-PD-1 therapy in combination with chemotherapy. A combination of immuno- and chemotherapy may become a promising conversion therapy for some molecular profiles of advanced GC.
Gastric cancer is a complex disease and needs to be treated in a complex way using all possible novel tools to improve patients’ outcomes. An individualized multimodal diagnosis and treatment of gastric cancer changes rapidly and we have to understand and implement all of these modalities into daily clinical life.
Prof. Dr. Wojciech P. Polkowski
Dr. Karol Polom
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gastric cancer
- molecular profile
- staging
- multimodality treatment
- precision surgical oncology
